

DIRECTORS AND SENIOR MANAGEMENT

DIRECTORS

Upon [REDACTED], our Board will consist of eight Directors, including two executive Directors, three non-executive Directors and three independent non-executive Directors. The following table provides certain information about our Directors:

Name ⁽¹⁾	Age	Position	Date of Joining the Group	Date of Appointment as our Director	Roles and Responsibilities
Mr. Tan Zheng (譚錚)	46	Chairman of the Board, executive Director, and chief strategy officer	December 20, 2020	April 25, 2023	Responsible for overseeing our overall strategic development and investment strategy
Dr. Wang Xiaoyi (王曉怡)	46	Executive Director, CEO and chief research officer	September 21, 2012	April 25, 2023	Responsible for products and technology research and development, overall operation, policies and business of the Group
Mr. Li Sirui (李思睿)	42	Non-executive Director	April 11, 2023	April 25, 2023	Responsible for providing strategic advice and recommendations on the operations and management of the Group
Ms. Li Mingqiu (李明秋)	42	Non-executive Director	July 30, 2023	July 30, 2023	Responsible for providing strategic advice and recommendations on the operations and management of the Group
Mr. Deng Feng	61	Non-executive Director	September 21, 2012 ⁽²⁾	April 25, 2023	Responsible for providing strategic advice and recommendations on the operations and management of the Group
Mr. Lam Yiu Por (林曉波)	48	Independent non-executive Director	[REDACTED]	[Appointed on [●], 2024, with effect from [REDACTED]]	Responsible for supervising and providing independent advice on the operations and management of the Group
Dr. Duan Tao (段濤)	60	Independent non-executive Director	[REDACTED]	[Appointed on [●], 2024, with effect from [REDACTED]]	Responsible for supervising and providing independent advice on the operations and management of the Group
Mr. Li Yuezhong (李月中)	54	Independent non-executive Director	[REDACTED]	[Appointed on [●], 2024, with effect from [REDACTED]]	Responsible for supervising and providing independent advice on the operations and management of the Group

DIRECTORS AND SENIOR MANAGEMENT

Notes:

- (1) Save as disclosed in “Relationship with Our Controlling Shareholders,” each of our Directors has no relationship with other Directors and senior management members of our Company as at the Latest Practicable Date.
- (2) Due to corporate reorganization of NLVC Shareholders, Mr. Deng Feng’s directorship in our Group was temporarily succeeded by another appointee of NLVC Shareholders between June 20, 2019 and April 21, 2022.

Executive Directors

Mr. Tan Zheng (譚錚), aged 46, was appointed as our Director in April 2023 and the chief strategy officer of our Group in December 2020, and was re-designated as the chairman of the Board and our executive Director in July 2023. Mr. Tan joined our Group in December 2020 and was appointed as a director of BrainAurora Zhejiang in the same time. Since then, Mr. Tan has made significant contributions to the Group’s business development by leveraging on his investment insights and business development capabilities, including (i) making judgment calls to screen and seize promising market opportunities relating to the System; (ii) identifying pathways for and overseeing the Group’s commercialization initiatives; and (iii) introducing and securing new investments in the Group from certain other [REDACTED] Investors.

Mr. Tan has served managerial positions at our subsidiaries, including those as set out below:

Name of Company	Position	Period of Service
Zhejiang Zhiling Ruidong Medical Technology Co., Ltd. (浙江智靈睿動醫療科技有限公司)	Chairman of the board	Since June 2023
Zhejiang BrainAurora Medical Technology Co., Ltd. (浙江腦動極光醫療科技有限公司)	Chairman of the board	Since December 2020

Through working with various pharmaceutical companies, Mr. Tan has over 20 years of experience in health and medical field. From June 1998 to June 2004, he worked at Shaanxi Buchang Pharmaceutical Co., Ltd. (陝西步長製藥有限公司), a company in China principally engaged in the development and manufacturing of medical drugs, where his last position was an office supervisor at their Tianjin office. From June 2004 to January 2013, Mr. Tan served as an office supervisor at the Beijing office of Shaanxi Kanghui Pharmaceutical Co., Ltd.* (陝西康惠控股有限公司), a company principally engaged in the research, development and production of pharmaceuticals products. Between January 2013 and August 2015, Mr. Tan worked at Wuhan Heer Medical Technology Development Co., Ltd. (武漢呵爾醫療科技發展有限公司), a company in China engaged in, among other things, the development and manufacture of cancer screening and analysis systems, first as an office supervisor at the Beijing office and subsequently as a deputy general manager, where he was responsible for

DIRECTORS AND SENIOR MANAGEMENT

sales, supervision and management of daily matters. Since September 2015 and March 2018, Mr. Tan has been serving as a director and the chairman of the board of directors, respectively, of Immunotech Applied Science Limited (北京永泰生物製品有限公司), a wholly-owned subsidiary of Immunotech Biopharm Ltd (永泰生物製藥有限公司) (“**Immunotech**”), a company listed on the Stock Exchange (stock code: 06978.HK). Since August 2019, Mr. Tan also has been serving as an executive director and the chairman of the board of directors in Immunotech.

Mr. Tan is currently pursuing an executive master’s degree in business administration from United Business Institutes China.

The Board has made appropriate enquiries with a view to understanding Mr. Tan’s work commitment in our Group and has considered Mr. Tan’s concurrent service as an executive Director of our Company and an executive director and chairman of the board of Immunotech Biopharm Ltd and is satisfied that Mr. Tan is able to devote sufficient time to perform his duties as an executive Director having regard to all relevant factors, including:

1. in the last three years since the listing of Immunotech Biopharm Ltd in July 2020, Mr. Tan has acquired extensive management experience and developed substantial knowledge on corporate governance through his directorship thereof, which are expected to facilitate his proper discharge of fiduciary duties and responsibilities as an executive director of a listed company;
2. when performing his roles of executive Director in our Company in formulating and executing business and investment strategies, annual operational and financial plans, Mr. Tan is assisted by his team of staff in dealing with the day-to-day matters in various aspects;
3. Mr. Tan has attended all applicable board meetings of Immunotech Biopharm Ltd since the listing of Immunotech Biopharm Ltd (as disclosed in its annual report for 2020, 2021 and 2022, respectively) and all applicable board meetings of the Company since his appointment in December 2020, therefore, the concurrent directorship did not hinder his time commitments in the Company in the past and it is expected that the concurrent directorship will also not affect his time commitments in the Company in the future; and
4. Mr. Tan has confirmed that: (a) Immunotech Biopharm Ltd has not questioned or complained about his time devoted to his directorship therein; and (b) he will have sufficient time to devote to his duties as an executive Director of our Company notwithstanding such other concurrent directorships.

As of the Latest Practicable Date, Mr. Tan does not have any interest in business which competes or is likely to compete, directly or indirectly, with our business and requires disclosure under Rule 8.10 of the Listing Rules. For details, see “Relationship with Our Controlling Shareholders — Competition.”

DIRECTORS AND SENIOR MANAGEMENT

Dr. Wang Xiaoyi (王曉怡), aged 46, was appointed as our Director in April 2023 and was re-designated as our executive Director in July, 2023. Dr. Wang has been serving as our CEO and chief research officer of our Group since June 2020.

Dr. Wang has served managerial positions at our subsidiaries, including those as set out below:

Name of Company	Position	Period of Service
Zhejiang Zhiling Ruidong Medical Technology Co., Ltd. (浙江智靈睿動醫療科技有限公司)	Director, manager	Since June 2023
Zhejiang BrainAurora Medical Technology Co., Ltd. (浙江腦動極光醫療科技有限公司)	General manager, director	Since September 2012
Shenzhen BrainAurora Medical Technology Co., Ltd. (深圳腦動極光醫療科技有限公司)	General manager, executive director	Since October 2023

Dr. Wang has over 15-year of experience in medical and health field. Between August 2009 and September 2010, Dr. Wang worked as a contractor in the radiology department in Xuanwu Hospital. From September 2010 to February 2013, Dr. Wang worked in Xuanwu Hospital as an employee engineer. Dr. Wang also has been serving as a member of the standing committee in China Society of Rehabilitation Medicine Special Committee on Telerehabilitation (中國康復醫學會遠程康復專委會) from December 2017 to December 2021, China Rehabilitation Medical Association Special Committee on AD and Cognitive Disorders Rehabilitation (中國康復醫學會AD與認知障礙康復專委會) since July 2021 and China Association of Gerontology and Geriatrics Nursing and Caregiving Branch (中國老年學與老年醫學學會護理與照護分會) since October 2018.

Specifically on the development of DTx products, including the System, our Company has been relying on Dr. Wang's leadership and supervision leveraged on his wealth of relevant experience and expertise as he has been dedicated to the fields of cognitive impairment screening, assessment, training and management for over ten years. He has also been involved in national level research and development projects organized under the 13th Five-Year Plan for Economic and Social Development of the People's Republic of China (中華人民共和國國民經濟和社會發展第十三個五年規劃), such as the 2017 Cerebrovascular Disease Exercise and Cognitive Rehabilitation System Management Program and the 2019 Major Chronic Non-Communicable Disease Prevention and Control Research Program. He also participated in the Regional Science Foundation Projects (地區自然科學基金項目), such as the 2019 Beijing Brain Program Major Project on the Development of Mobilized Targeted Intervention Technology for Schizophrenia Based on Comprehensive Cognitive Function Assessment. Dr.

DIRECTORS AND SENIOR MANAGEMENT

Wang’s involvement in these major projects and his long-term research in the treatment of cognitive impairment provide him with the industry experience necessary to guide our cognitive impairment DTx research and development.

Dr. Wang obtained a bachelor’s degree in biology from College of Life Sciences, Beijing Normal University (北京師範大學生命科學學院) in China, in July 2000 and graduated from the Institute of Psychology, Chinese Academy of Sciences (中國科學研究院心理研究所) in China where he majored in applied psychology, in July 2005. Dr. Wang also obtained a doctor’s degree in basic psychology from State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University (北京師範大學認知神經科學與學習國家重點實驗室) in China, in June 2009.

Non-executive Directors

Mr. Li Sirui (李思睿), aged 42, was appointed as a Director in April 2023 and was re-designated as our non-executive Director in July, 2023.

Mr. Li has approximately 15-year of experience in investment. He served as the vice president and general manager of strategic planning in Huajing (Tianjin) Investment Management Co., Ltd. (華金(天津)投資管理有限公司) from May 2012 to January 2016. Mr. Li has served as the analyst of Shenzhen Chongshi Private Equity Fund Management Co., Ltd. (深圳崇石私募股權投資基金管理有限公司) from September 2007 to May 2012. He has been serving as the director of strategic investment department in Tasly Pharmaceutical Group Co., Ltd (天士力醫藥集團股份有限公司), a company listed on the Shanghai Stock Exchange (Stock code: 600535) since April 2024, and the general manager of strategy development center at Tasly Biopharmaceuticals Industry Group Co., Ltd. (天士力生物醫藥產業集團有限公司) (formerly known as Tasly Holding Group Co., Ltd. (天士力控股集團有限公司)) since July 2020. He also served as the executive vice president and then the general manager of Juzhida Health Technology Services Group Co., Ltd. (聚智大健康科技服務集團有限公司) since March 2020.

Mr. Li obtained a bachelor’s degree in pharmaceutical engineering from Tianjin University (天津大學) in China, in June 2005. He obtained a master’s degree in business administration from Nankai University in China, in December 2014. Mr. Li has been a member of China Institute of Internal Audit (CIIA) since March 2011.

Ms. Li Mingqiu (李明秋), aged 42, was appointed as our Director in July 2023 and was re-designated as our non-executive Director in July 30, 2023.

Since January 2022, Ms. Li has been serving as the insurance business manager in Taiping Life Insurance Company Limited Liaoning Branch (太平人壽保險有限公司遼寧分公司). She also served as the executive director in Tianjin Tianjian Medical Technology Co. Ltd. (天津天健醫療科技有限公司).

Ms. Li obtained bachelor’s degree in software engineering from University of Science and Technology Anshan (鞍山科技大學) (currently know as University of Science and Technology Liaoning (遼寧科技大學)) in China in July 2006.

DIRECTORS AND SENIOR MANAGEMENT

Mr. Deng Feng, aged 61, has served as our director since April 2023 and was re-designated as our non-executive Director on July 30, 2023.

Mr. Deng has over 22 years of experience in venture capital, computer science and telecommunication industry. He founded Northern Light Venture Capital in January 2006 and served as its founding managing partner, focusing on investment in technology, media and telecom, or technology, media and telecom, clean technology, healthcare and consumer sectors. He obtained a bachelor’s and a master’s degree in electronic engineering from Tsinghua University in China in July 1986 and December 1988, respectively, a master’s degree in computer engineering from the University of Southern California in U.S. in August 1993, and a master of business administration degree from the Wharton Business School of the University of Pennsylvania in U.S. in May 2005. Mr. Deng served as a director in New Hope Group (新希望集團有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 000876.SZ), from September 2016 to May 2022. Mr. Deng also served as a director in iRay Technology Company Limited (上海奕瑞光電子科技股份有限公司) from July 2017 to March 2022. Mr. Deng has been serving as a director in Burning Rock Biotech Ltd., a company listed on Nasdaq (stock ticker: BNR) since August 2016. He also served as a director in Hillstone Network Communication Technology Co. (山石網科通信技術股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688030.SH), from December 2018 to January 2022. From August 2018 to June 2022, he served as a director in Cytex Biosciences Inc., a company listed on Nasdaq (stock ticker: CTKB).

Independent Non-executive Directors

Mr. Lam Yiu Por (林曉波), aged 48, [has been] appointed as an independent non-executive Director with effect from the [REDACTED]. He is primarily responsible for supervising and providing independent advice on the operations and management of the Group.

Mr. Lam has been serving as an independent non-executive director in JNBY Design Limited (江南布衣有限公司), a company listed on the Stock Exchange (stock code: 03306.HK) since October 13, 2016, and an independent non-executive director in Xiamen Yan Palace Bird’s Nest Industry Co., Ltd. (廈門燕之屋燕窩產業股份有限公司), a company listed on the Stock Exchange (stock code: 01497.HK), since November 20, 2023. Since January 2021, Mr. Lam has been serving as the chief financial officer and joint company secretary of Dingdang Health Technology Group Ltd. (叮噹健康科技集團有限公司), a company listed on the Stock Exchange (stock code: 09886.HK). He served as the vice president and chief financial officer of Greentech Technology International Limited (綠科科技國際有限公司), a company listed on the Stock Exchange (stock code: 00195.HK), from November 2013 to July 2020. He served as an independent non-executive director of Tian Ge Interactive Holdings Limited (天鵝互動控股有限公司), a company listed on the Stock Exchange (stock code: 01980.HK), from January 2021 to June 2022. From December 2014 to March 2016, Mr. Lam served as an independent non-executive director of Yat Sing Holdings Limited (日成控股有限公司), a company listed on the Stock Exchange (stock code: 03708.HK, currently known as China Supply Chain Holdings Limited (中國供應鏈產業集團有限公司)). From April 2015 to May 2017, Mr. Lam served as a non-executive director of Zhong Ao Home Group Limited (中奧到家集團有限公

DIRECTORS AND SENIOR MANAGEMENT

司), a company listed on the Stock Exchange (stock code: 01538.HK). From October 2015 to June 2020, Mr. Lam served as an independent non-executive director of Denox Environmental & Technology Holdings Limited (迪諾斯環保科技控股有限公司), a company listed on the Stock Exchange (stock code: 01452.HK). From November 2016 to November 2018, Mr. Lam served as an independent non-executive director of China Tontine Wines Group Limited (中國通天酒業集團有限公司), a company listed on the Stock Exchange (stock code: 00389.HK). From June 2012 to February 2014, he was an independent non-executive director and chairman of the audit committee of GR Properties Limited (國銳地產有限公司), a company listed on the Stock Exchange (stock code: 00108.HK, formerly known as Buildmore International Limited). Mr. Lam also served as the chief financial officer and company secretary of Lijun International Pharmaceutical (Holding) Co., Ltd. (利君國際醫藥(控股)有限公司) (currently known as SSY Group Limited (石四藥集團有限公司)), a company listed on the Stock Exchange (stock code: 2005) from December 2005 to May 2008 and the chief financial officer and qualified accountant of Zhongtian International Holdings Limited (中天國際控股有限公司) (currently known as China Clean Energy Technology Group Limited (中國清潔能源科技集團有限公司)), a company listed on the Stock Exchange (stock code: 2379) from July 2004 to December 2005.

Mr. Lam received his bachelor’s degree of arts in accountancy from the Hong Kong Polytechnic University (香港理工大學) in November 1997. Mr. Lam is a member of the Hong Kong Institute of Certified Public Accountants, an associate of The Hong Kong Chartered Governance Institute (formerly known as The Hong Kong Institute of Chartered Secretaries), a chartered financial analyst of the CFA Institute, and a fellow of the Association of Chartered Certified Accountants.

Dr. Duan Tao (段濤), aged 60, [has been] appointed as an independent non-executive Director with effect from the [REDACTED]. He is primarily responsible for supervising and providing independent advice on the operations and management of the Group.

Since August 2000, Dr. Duan has been serving as the vice president and then the president Shanghai First Maternity and Infant Health Hospital of Tongji University (同濟大學附屬上海市第一婦嬰保健院). Dr. Duan has served as the project leader of the National Key Research and Development Program (國家重點研發計劃項目負責人) from July 2018 to December 2020 for “Research and Development of New Technologies for Intrauterine Diagnosis and Treatment of Major Fetal Diseases (重大胎兒疾病宮內診斷和治療新技術研發).” He has been awarded as the Shanghai Excellent Discipline Leader (上海市優秀學術帶頭人) for the year of 2014 and Shanghai Medical Leader (上海市醫學領軍人才) for the year of 2015.

Dr. Duan graduated from Shandong Medical University (山東醫科大學, currently known as Shandong University Cheeloo College of Medicine (山東大學齊魯醫學院)) and majored in medicine in China in July 1987. He obtained a doctor’s degree of medicine in Shanghai Medical University (上海醫科大學) (currently known as Shanghai Medical College of Fudan University (復旦大學上海醫學院)) in China in July 1992.

DIRECTORS AND SENIOR MANAGEMENT

Mr. Li Yuezhong (李月中), aged 54, [has been] appointed as an independent non-executive Director with effect from the [REDACTED]. He is primarily responsible for supervising and providing independent advice on the operations and management of the Group.

From May 2000 to July 2005, Mr. Li was an executive director at UB China Business Management Co. Ltd. (友聯中國業務管理有限公司), a subsidiary of Industrial and Commercial Bank of China (Asia) Limited (“ICBC (Asia)”), a company listed on the Stock Exchange (stock code: 01398.HK), engaging in the management of the impaired loan portfolio of ICBC (Asia) in the PRC. From July 2005 to May 2009, he was an assistant general manager at China Merchants China Investment Management Limited (招商局中國投資管理有限公司), a fund management company incorporated in Hong Kong, where he was responsible for supervising project investment and management. From June 2009 to February 2019, he was a joint managing director at CCB International Asset Management Limited (建銀國際資產管理有限公司), an asset management company established in Hong Kong. From February 2019 to June 2021, he has been a joint general manager of Greater Bay Area Development Fund Management Limited (大灣區發展基金管理有限公司), a Hong Kong company that provides fund investment financing services to professional investors, where he is responsible (along with other managers and responsible officers) for managing Greater Bay Area Development Fund Management Limited’s role as the investment manager of Greater Bay Area Homeland Development Fund LP. Mr. Li also served as a non-executive director of Immunotech Biopharm Ltd (永泰生物製藥有限公司), a company listed on the Stock Exchange (stock code: 06978.HK) from August 2019 to August 2021. Since January 2022, Mr. Li has been serving as a director in Beijing Boru Xincheng Investment Management Co., Ltd. (北京博儒信誠投資管理有限公司). Since May 2022, he has been serving as an independent director in Guizhou Guotai Intelligent Liquor Group Co., Ltd. (貴州國臺數智酒業集團股份有限公司) (formerly known as Guizhou Guizhou Guotai Liquor Group Co., Ltd. (貴州國臺酒業集團股份有限公司)).

In June 1993, Mr. Li obtained a bachelor’s degree in finance from Hunan University of Finance and Economics (湖南財經學院), (currently known as Hunan University (湖南大學)) in the PRC. In December 2005, he received a master’s degree in finance from University of Hong Kong.

Other Disclosure Pursuant to Rule 13.51(2) of the Listing Rules

Save as disclosed above and in this Document, each of our Directors confirms with respect to himself or herself that he or she (i) did not hold other long positions or short positions in the Shares, underlying Shares, debentures of our Company or any associated corporation (within the meaning of Part XV of the SFO) as of the Latest Practicable Date; (ii) had no other relationship with any Directors, senior management or substantial shareholders of our Company as of the Latest Practicable Date; (iii) did not hold any other directorships in the three years prior to the Latest Practicable Date in any public companies of which the securities are listed on any securities market in Hong Kong and/or overseas; and (iv) there are no other matters concerning his or her appointment that need to be brought to the attention of our Shareholders and the Stock Exchange or shall be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

DIRECTORS AND SENIOR MANAGEMENT

SENIOR MANAGEMENT

The following table sets out information regarding the members of senior management of our Company:

Name	Age	Position	Date of Joining the Group	Date of Appointment as our senior management	Roles and Responsibilities
Mr. Tan Zheng (譚錚)	46	Chairman of the Board, executive Director, and chief strategy officer	December 20, 2020	December 20, 2020	Responsible for overseeing our overall strategic development and investment strategy
Dr. Wang Xiaoyi (王曉怡)	46	Executive Director, CEO and chief research officer	September 21, 2012	September 21, 2012	Responsible for products and technology research and development, overall operation, policies and business of the Group
Mr. Cai Longjun (蔡龍軍)	41	Chief technology officer and chief operating officer	January 17, 2022	January 17, 2022	Responsible for developing technology strategies
Mr. Wang Junjie (王俊傑)	38	CFO	September 6, 2021	September 6, 2021	Responsible for overseeing the financial affairs of the Group
Mr. Lai Zhiyuan (賴知遠)	40	Vice president of market and operation	October 8, 2021	October 8, 2021	Responsible for management of sales and customer service, and daily operation

Mr. Tan Zheng (譚錚) aged 46, is the chairman of the Board, executive Director and chief strategy officer. For details of his biography, see subsection headed “— Directors — Executive Directors” above.

Dr. Wang Xiaoyi (王曉怡), aged 46, is an executive Director, CEO and chief research officer. For details of her biography, see subsection headed “— Directors — Executive Directors” above.

Mr. Cai Longjun (蔡龍軍), aged 41, was appointed as our chief technology officer and chief operating officer in January 2022. Mr. Cai is responsible for developing technology strategies.

Mr. Cai has approximately 15-year of experience in computer science. Mr. Cai has served as the software developer in International Commercial Machine (China) Investment Co., Ltd. (國際商業機器(中國)投資有限公司), the subsidiary of International Business Machines Corporation, a company listed on Nasdaq (stock ticker: IBM) from July 2008 to October 2012. From September 2012 to October 2016, he served as a scientist in Beijing Qiyi Century Technology Co., Ltd. (北京奇藝世紀科技有限公司), the subsidiary of iQIYI, Inc., a company

DIRECTORS AND SENIOR MANAGEMENT

listed on Nasdaq (stock ticker: IQ). From February 2017 to January 2022, he served a senior algorithm expert in the branch of Youku Network Technology (Beijing) Co., Ltd. (優酷網絡技術(北京)有限公司), the subsidiary of Alibaba Group Holding Limited, a company listed on the Stock Exchange (stock code: 09988.HK) and the Nasdaq (stock ticker: BABA).

The above various managerial and technical roles which Mr. Cai has assumed in such major international internet companies provide him the skills, experience and expertise in the files of big data, algorithms, internet technologies, and project development. These are transferable and necessary to him discharging the roles as our chief technology officer and chief operating officer which, among others, require him to have acquired deep insights and necessary technological know-hows in the DTx industry that heavily involves the above mentioned technologies as well.

Mr. Cai obtained a bachelor’s degree in Beijing Jiaotong University (北京交通大學) in China in July 2006 and also a master’s degree in Beijing Jiaotong University in June 2008.

Mr. Wang Junjie (王俊傑), aged 38, was appointed as our financial director in September 2021. Mr. Wang is responsible for overseeing the financial affairs of the Group.

Mr. Wang has over 10-year of experience in finance and investment. He served as an auditor and senior auditor from October 2009 to May 2012 and an audit manager, from February 2014 to February 2017 in Beijing branch of Deloitte Touche Tohmatsu. From November 2012 to February 2014, he served as an investment manager in Beijing Xinglian Cheng Investment Management Co. Ltd. (北京星聯程投資管理有限公司). Mr. Wang also served as the financial director in Beijing YingYan Network Technology Co. Ltd. (北京盈衍網路科技有限公司), from March 2017 to August 2018. From November 2019 to March 2020, Mr. Wang served as the head of internal audit in China Submarine Co., Ltd. (中潛股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 300526.SZ) previously and delisted in July 2023. He also served as the financial director in Beijing Jing Shi Hongru Education Technology Co., Ltd. (北京京師鴻儒教育科技有限公司), from May 2020 to August 2021.

Mr. Wang obtained a bachelor’s degree in management from Peking University (北京大學) in China, in July 2009. He is also a member of non-practicing certified public accountants in China (中國非執業註冊會計師).

Mr. Lai Zhiyuan (賴知遠), aged 40, was appointed as our vice president of market and operation in October 2021. He is responsible for management of sales and customer service, and daily operation.

Mr. Lai served as the general manager of business affairs department in Beijing Chunyu Tianxia Software Co., Ltd. (北京春雨天下軟件有限公司), from February 2014 to June 2017. He also served as senior vice president in Dingdang Fast Medicine Technology Group Co., Ltd. (叮噹快藥科技集團有限公司), from May 2017 to May 2018. From June 2018 to June 2019, he served as general manager of health management center in Ransheng Health Industry

DIRECTORS AND SENIOR MANAGEMENT

Investment Co. Ltd. (冉盛健康產業投資有限公司). Mr. Lai also served as the joint founder and general manager in Jiangsu Xijie Biotechnology Co., Ltd. (江蘇稀捷生物科技有限公司), from August 2019 to September 2021.

Mr. Lai obtained a bachelor’s degree in acupuncture in Chinese medicine from Fujian College of Traditional Chinese Medicine (福建中醫學院) (currently know as Fujian University of Traditional Chinese Medicine (福建中醫藥大學)) in China, in July 2007.

JOINT COMPANY SECRETARIES

Mr. Wang Junjie (王俊傑) was appointed as a joint company secretary of our Company on July 30, 2023. For details of his biography, see subsection headed “Senior Management” above.

Ms. Sham Ying Man (岑影文) was appointed as a joint company secretary of our Company on July 30, 2023. Ms. Sham is a manager of Company Secretarial Services of Tricor Services Limited, a global professional services provider specializing in integrated business, corporate and investor services. She has over 25 years of experience in the corporate secretarial field.

Ms. Sham currently holds company secretary positions in certain Hong Kong listed companies, including Hilong Holding Limited (海隆控股有限公司) (stock code: 1623), Honma Golf Limited (本間高爾夫有限公司) (stock code: 6858) and WuXi Biologics (Cayman) Inc. (藥明生物技術有限公司) (stock code: 2269).

Ms. Sham obtained a bachelor degree of business administration from Lingnan College (now known as Lingnan University). She is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom, respectively.

Our Company [was granted] a waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules such that Mr. Wang Junjie and Ms. Sham may be appointed as joint company secretaries of our Company, on the condition that the waiver can be revoked if there are material breaches of the Listing Rules by our Company. For details, please refer to the section headed “Waivers — Waiver in respect of Joint Company Secretaries.”

CORPORATE GOVERNANCE

Audit Committee

We have established an audit committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The audit committee of the Company comprises three members, namely Mr. Lam Yiu Por, Mr. Li Yuezhong and Dr. Duan Tao, with Mr. Lam Yiu Por (being our

DIRECTORS AND SENIOR MANAGEMENT

independent non-executive Director with the appropriate professional qualifications or accounting or related financial management expertise as required under Rules 3.10(2) and 3.21 of the Listing Rules) as chairman of the audit committee. The primary duties of the Company’s audit committee are, among other things, to review and supervise the financial reporting process and internal controls system of our Group, review and approve connected transactions and provide advice and comments to the Board.

Remuneration Committee

We have established a remuneration committee with written terms of reference in compliance with Rule 3.25 of the Listing Rules and the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The remuneration committee of the Company comprises three members, namely Mr. Li Yuezhong, Mr. Lam Yiu Por and Dr. Duan Tao, with Mr. Li Yuezhong as chairman of the remuneration committee. The primary duties of the Company’s remuneration committee are to review and make recommendations to the Board on the terms of remuneration packages, bonuses and other compensation payable to our Directors and other senior management.

Nomination Committee

We have established a nomination committee with written terms of reference in compliance with Rule 3.27A of the Listing Rules and the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The nomination committee of the Company comprises three members, namely Mr. Tan Zheng, Mr. Li Yuezhong and Dr. Duan Tao, with Mr. Tan Zheng as chairman of the nomination committee. The primary duties of the nomination committee are to make recommendations to our Board on the appointment of Directors and management of Board succession.

Board Diversity Policy

We are committed to promoting the culture of diversity in the Company. We have strived to promote diversity to the extent practicable by taking into consideration a number of factors in our corporate governance structure.

Our Company has adopted a board diversity policy which sets out the objective and approach to achieve and maintain diversity of the Board in order to enhance the effectiveness of our Board. Pursuant to the board diversity policy, we seek to achieve Board diversity through the consideration of a number of factors, including but not limited to gender, age, educational background, industry experience and professional experience. Our Directors have a balanced mix of gender, knowledge, skills and experiences, including management, strategic planning, finance, investment, healthcare and technology industries. They obtained degrees in various areas such as biology, medical, business administration, communication and electronic system and computer engineering. We have also taken, and will continue to take steps to promote gender diversity at the Board level of our Company. Upon [REDACTED], our Board comprises seven male members and one female members, and we expect to maintain/improve

DIRECTORS AND SENIOR MANAGEMENT

such gender ratio at the Board level going forward. After [REDACTED], the nomination committee will revisit the board diversity policy and monitor its implementation from time to time. Our nomination committee will also use their best efforts to identify and recommend suitable female candidates for the Board's consideration in the future to ensure that gender diversity can be maintained. With reference to our board diversity policy, we will also ensure that there is gender diversity when recruiting staff at mid to senior level so that we will have a pipeline of female senior management and potential successors to our Board in due time to ensure gender diversity of the Board. Our Group will continue to emphasize training of female talent and providing long-term development opportunities for our female staff.

Anti-Corruption and Whistle Blowing Policies

We are committed to acting with integrity, honesty, fairness, impartiality, and ethical business practices. We have adopted an anti-corruption policy to promote an ethical culture within our Group and have zero-tolerance for bribery and any kind of corrupt activities. Our Board and senior management also strive to promote an ethical culture within our Group. We also adopted a whistle blowing policy that serves the purpose of establishing whistleblowing procedures for employees and other relevant external parties of our Group, in order to report and escalate any suspicious misconducts. In accordance with the policy, we protect all whistleblowers from any kind of retaliation. All the information provided by the whistleblowers will be strictly confidential.

Corporate Governance Code

We aim to achieve high standard of corporate governance which are crucial to our development and safeguard the interests of our Shareholders. In order to accomplish this, we expect to comply with the Corporate Governance Code set out in Appendix C1 to the Listing Rules.

KEY TERMS OF EMPLOYMENT CONTRACTS

We normally enter into an employment contract with non-competition clauses with our key management members and technical personnel. We normally enter into an employment contract with our key management members and technical personnel with a term of three years. Below sets forth the key terms of these contracts we enter into with our key management members and technical personnel.

Confidentiality

Scope of confidential information: Information the employee shall keep confidential includes but is not limited to: technical information and business information that is not known to the public, can bring economic benefits to the enterprise, is practical and has been kept confidential by the Company.

DIRECTORS AND SENIOR MANAGEMENT

Confidential obligation: The employee (i) shall keep the Company's trade secrets known to him or her by virtue of his or her status, position, occupation or technical relationship, and shall guarantee that they will not be disclosed or used, including by accident or negligence. This is so even though the information may have been conceived or acquired in its entirety by the person subject to confidentiality as a result of his or her work; (ii) during the period of labor relationship, shall not (a) disclose or use the trade secrets without authorization for the purpose of competition, or for personal interest, or for the benefit of a third party, or for the purpose of intentionally inflicting harm on the Company, (b) spy on the trade secrets which are not related to his/her own work or his/her own business; shall not divulge them, directly or indirectly, to unrelated persons inside or outside the Company, (c) disclose the trade secrets of the Company to any third party who does not bear the obligation of confidentiality, and (d) copy or publicize the documents or copies of documents containing the Company's trade secrets; and (iii) shall treat the documents related to the Company, the Company's customers and the Company's partners that are kept and touched by the work properly, and shall not use them beyond the scope of work without permission.

Confidential period: The confidentiality obligation shall continue to be in effect during the course of employment and after the departure of the employee.

Ownership of intellectual work products

The right of use, license, ownership and related intellectual property rights of any technology, software and other results developed by the employee using the Company's information, materials, substances, equipment and tools shall belong to the Company, and the employee shall not use or license others to use them without authorization or take them for himself/herself. If, without the Company's consent, the employee applies for a patent or copyright registration in the name of the employee and/or a third party, the employee agrees to exclusively transfer the above technology, software, copyright, patent right, patent application right and any related rights to the Company at a transfer fee of RMB1 per piece. Staff undertakes not to use any of the above technical results, works, software, patents, etc. for commercial purposes or to license others to use them for commercial purposes without the written consent of the Company.

Non-competition

Term and Scope: The non-competition obligation is effective during the course of employment. The employee shall bear the non-competition obligation him or herself, and cause and procure his or her affiliates (including but not limited to, his or her spouse, children, brothers and sisters, parents, relatives by law, grandparents, grandchildren, uncles, aunts and cousins) to also keep non-competition obligation.

Non-competition obligation: The employee shall not, and shall cause and procure that his/her affiliates shall not, without the prior written consent of the Company, directly or indirectly, carry on or be in any way interested in any and all business worldwide, which competes or proposes to compete with the Group's business, whether (i) in the capacity of sole

DIRECTORS AND SENIOR MANAGEMENT

proprietorship, shareholding, investing, partnership, licensors or in any other way; (ii) by acting as a consultant (or provide consultancy service or similar service), employee or officer in any capacity in such business or providing technical, commercial or professional advice to such business; (iii) by supplying any product or service of the same type as or similar to or competitive with any product or service supplied by the Group to any person who is a customer of the Group; or (iv) by manufacturing, marketing, selling and distributing products worldwide that are identical to or compete with any products of such business, or in any way compete with the Group.

COMPENSATION OF DIRECTORS AND SENIOR MANAGEMENT

Our Directors receive compensation in the form of salaries, other allowances, retirement benefits, and equity settled share-based payments. Our Directors’ remuneration is determined with reference to the relevant Director’s experience and qualifications, level of responsibility, performance and the time devoted to our business, and the prevailing market conditions. For the terms of service contracts and appointment letters with our Directors, please refer to the section headed “Appendix IV — Statutory and General Information.”

The aggregate amount of remuneration to our Directors for the three years ended December 31, 2023, and the six months ended June 30, 2024 were approximately RMB15.1 million, RMB4.8 million, RMB37.0 million and RMB24.2 million, respectively. It is estimated that remuneration and benefits in kind (excluding any possible payment of discretionary bonus) equivalent to approximately RMB45.9 million in aggregate will be paid and granted to our Directors by us in respect of the financial year ending December 31, 2024 under arrangements in force at the date of this Document.

The aggregate amount of remuneration to our five highest paid individuals who are neither Director nor chief executive of our Company for the three years ended December 31, 2023 and the six months ended June 30, 2024 were approximately RMB6.5 million, RMB4.4 million, RMB10.7 million and RMB8.7 million, respectively.

[REDACTED] SHARE AWARD SCHEME

We have approved and adopted the [REDACTED] Share Award Scheme, the principal terms of which are summarized in “Appendix IV – Statutory and General Information – [REDACTED] Share Award Scheme.”

During the Track Record Period, (i) no remuneration was paid to our Directors or the five highest paid individuals as an inducement to join, or upon joining our Group; (ii) no compensation was paid to, or receivable by, our Directors, past Directors or the five highest paid individuals for the loss of office as director of any member of our Group or of any other office in connection with the management of the affairs of any member of our Group; and (iii) none of our Directors waived any emoluments.

DIRECTORS AND SENIOR MANAGEMENT

For additional information on remuneration of our Directors and the highest paid individuals, see Notes 12 and 13 to the Accountants' Report.

COMPLIANCE ADVISER

Our Company has appointed SPDB International Capital Limited as our Compliance Adviser pursuant to Rule 3A.19 of the Listing Rules. Pursuant to Rule 3A.23 of the Listing Rules, our Compliance Adviser will advise our Company in the following circumstances:

- before the publication of any regulatory announcement, circular or financial report;
- where a transaction, which might be a notifiable or connected transaction, is contemplated, including shares issues, sales or transfers of treasury shares and share repurchases;
- where our Company proposes to use the [REDACTED] of the [REDACTED] in a manner different from that detailed in this Document or where our business activities, developments or results deviate from any forecast, estimate or other information in this Document; and
- where the Stock Exchange makes an inquiry of our Company under Rule 13.10 of the Listing Rules.

The term of the appointment of our Compliance Adviser shall commence on the [REDACTED] and end on the date on which our Company distribute our [REDACTED] in respect of our financial results for the first full financial year commencing after the [REDACTED].

CONFIRMATION FROM OUR DIRECTORS

Rule 8.10 of the Listing Rules

Each of our Directors confirms that as of the Latest Practicable Date, he or she did not have any interest in a business which competes or is likely to compete, directly or indirectly, with our business and requires disclosure under Rule 8.10 of the Listing Rules.

From time to time our non-executive Directors may serve on the boards of both private and public companies within the broader healthcare and biopharmaceutical industries. However, as these non-executive Directors are not members of our executive management team, we do not believe that their interests in such companies as directors would render us incapable of carrying on our business independently from the other companies in which these non-executive Directors may hold directorships from time to time.

DIRECTORS AND SENIOR MANAGEMENT

Rule 3.09D of the Listing Rules

Each of our Directors confirms that he/she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules on July 30, 2023, and (ii) understands his or her obligations as a director of a listed issuer under the Listing Rules.

Rule 3.13 of the Listing Rules

Each of the independent non-executive Directors has confirmed (i) his independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Listing Rules, (ii) that he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person of the Company under the Listing Rules as of the Latest Practicable Date, and (iii) that there are no other factors that may affect his independence at the time of his appointments.